Key facts
- This page summarizes Jonathan Anderman's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Apr 2025, 09:30.
Jonathan Anderman - 07 Apr 2025 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)
- Reporting relationship
- Gen Counsel & Corporate Sec
- Issuer ticker
- CMPX
- Reported as of
- 07 Apr 2025
- Net transaction value
- +$30,800
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2025, 09:30:55 UTC
- Prior SEC filing
- 13 Feb 2025
- Next SEC filing
- 05 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Neil Lerner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Anderman filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 08 Apr 2025.
Change
- Previous filing in this sequence was filed on 13 Feb 2025.
- Current net transaction value: +$30,800.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMPX
transaction
Common Stock
Purchase
- Transaction value
- $30,800
- Shares
- +20,000
- Change %
- +2000%
- Price
- $1.54
- Shares after
- 21,000
- Date
- 07 Apr 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.